Pfizer sets up Asia's first global drug development centre in Chennai
Chennai (Tamil Nadu), May 4: In a bid to bring critical research and development capabilities under one roof, pharmaceutical firm Pfizer has set up a global drug development centre at the IIT Madras Research Park in Chennai, Tamil Nadu.
The capabilities of the centre will include the development of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) of differentiated products like complex/value-added formulations, controlled-release dosage forms, device-combination products, lyophilized injections, powder-fill products, and ready-to-use formulations. It will also create and support products in global markets and Pfizer's manufacturing centres worldwide.
" Pfizer's drug development centre in the IIT Madras Research Park is a positive opportunity to establish truly one of the most advanced laboratories that Pfizer is setting up for R&D in the aforementioned disciplines anywhere in Chennai and in the world," informed S Sridhar, Country Manager of Pfizer India.
Also Read | MHA seeks report from Rajasthan over communal tension in Jodhpur
"We are confident that it will allow for synergistic co-development of cutting-edge API and FDF processes under the same roof. The world-class scientific, technology and innovation-driven Research Park campus provide an ideal setting for our work. We are hopeful that the proximity to IIT Madras and other technology Research Park start-ups will also improve academia and industry partnerships and encourage greater collaboration to drive innovation," he said.
Pfizer has invested USD 20 million (INR 150 crore) in the IIT Madras Research Park's 61,000-square-foot research and technology centre. While this centre will be part of a global network of 12 global centres, it will be Pfizer's first and only one in Asia at this time.
Also Read | European Commission announces large-scale package of aid to Ukraine
-PTC News
